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Introduction 
Decades of research has shown that sleep plays a vital role in our health, and disruptions 
in sleep can have long term detrimental effects on our lives (Yoo, 2007). The recommended 
amount of sleep by the National Sleep Foundation (NSF) for adults is between 7-9 hours each 
night (NSF, 2020). It is common knowledge that too few hours of sleep are unhealthy, but 
scientists are only beginning to understand the mechanisms that explain the connections between 
sleep patterns and health outcomes (CDC, 2011). Additionally, recent research has shown that 
excess sleep can be just as detrimental, if not more, to health outcomes (Patel, 2009). One of the 
reasons that poor sleep can be a negative consequence for health is because sleep disruptions can 
lead to inflammation (Patel, 2009). Inflammation is often a positive event that is occurring in the 
body because it signifies that the body is healing. When a person gets a cut, the area around the 
wound becomes inflamed because inflammatory biomarkers are being called to the area to 
promote repair. However, too much inflammation can have negative consequences. If a person is 
consistently getting poor sleep, then their body believes that it is constantly needing repair. This 
activates the immune system and the previously mentioned inflammatory biomarkers are called 
to respond (Mullington, 2010). These biomarkers, which normally help to heal areas of damage, 
might cause the immune system to attack areas of healthy tissue, therefore causing damage rather 
than repairing damage. Therefore, it is important to understand how this affects chronic health. 
Chronic disease and inflammatory processes often coincide. When a patient has a chronic health 
condition, their immune system is activated and is sending inflammatory biomarkers to respond 
(Laveti, 2013). However, the question of whether the elevated levels of biomarkers are a side 
effect of the chronic disease or a cause of the disease is unknown. If it is a cause, then it is 
possible that poor sleep resulting in high levels of biomarkers could lead to chronic disease. In 
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the current review, research on the effects of inflammatory biomarkers that are elevated as a 
result of sleep is examined as well as the role that these biomarkers play in the increased risk for 
chronic health diseases. 
Review of Literature 
 To begin this review, it is necessary to understand the process of inflammation and the 
role it plays in the body. The three biomarkers that will be discussed all have their own functions 
during the inflammatory response, and in order to evaluate the effect that they have on sleep and 
chronic disease, these jobs need to be fully understood. Once the biomarkers are discussed, the 
relationship that they have with sleep will be discussed. There are many aspects of sleep to 
examine including sleep duration, sleep efficiency, and sleep disorders. Research has shown that 
sleep impacts biomarker levels, but it needs to be further examined to determine how this can 
affect chronic disease (Patel, 2009). Chronic health issues are associated with inflammatory 
biomarkers, but this relationship will be discussed further in order to determine the process 
through which sleep predicts chronic health conditions via inflammatory biomarkers (Laveti, 
2013). At the end of this review, the relationship between these three variables, sleep, 
inflammatory biomarkers, and chronic health disease, will be discussed. 
Inflammatory Biomarkers 
Inflammation is the body’s reaction to invasion or infection. If either event occurs, the 
body signals the immune system to repair damaged tissue (Szalay, 2019). Cytokines are the 
actual components that signal the immune system to respond in a specific area of the body that is 
being invaded. They are involved in cell signaling and ultimately leave a chemical trail, leading 
the different molecules involved in healing to the area of injury (Black, 2004). When cytokines 
are elevated, this indicates that the body’s immune system has been triggered, and there is 
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inflammation occurring somewhere in the body. Numerous cytokines are being studied regarding 
their relationship to chronic inflammation and sleep. The current review focuses on the 
inflammatory biomarkers, C-Reactive Protein (CRP), Interleukin-6 (IL-6), and Tumor Necrosis 
Factor-alpha (TNF-𝛼) since prior literature has emphasized their connections with sleep issues 
and chronic health outcomes.  
C-Reactive Protein 
One crucial inflammatory biomarker is C-reactive protein. CRP is a plasma protein that is 
actively involved in the body’s systemic response to inflammation. Many inflammatory 
biomarkers have multiple effects as a result of a single gene and this includes CRP because it has 
both proinflammatory and anti-inflammatory effects (Black, 2004). CRP affects inflammation 
through the role it plays in the complement system, which is a pathway that causes inflammation 
to occur (Black, 2004). CRP can mediate the pathway by binding to specific carbohydrates. This 
leads to the release of proinflammatory cytokines which as mentioned earlier, attract white blood 
cells to the area that requires healing. When CRP binds to the carbohydrate it causes 
opsonization of the target cell. Opsonization is the process by which a cell is coated so that 
macrophages, a type of white blood cell, can easily engulf and break down the cell through the 
process called phagocytosis. Phagocytosis is then upregulated meaning macrophages ingest 
foreign particles and remove them from the cell tissue (Black, 2004). This then causes an 
elevation in serum levels, therefore indicating the occurrence of an inflammatory response. 
With each acute inflammation stimulus, the plasma level of CRP may rise as much as 
1000-fold and more (Black, 2004). These CRP levels are used as a test by medical professionals 
in order to predict a patient’s risk of developing cardiovascular disease in the future. According 
to the American Heart Association, CRP tests are beneficial in predicting the risk of patients who 
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have a 5-10% chance of having a heart attack in the next ten years (Mayo Clinic, 2017). This test 
is also used to predict risk of having a second heart attack in patients who have already 
experienced their first heart attack. Studies have found that CRP levels also have a strong 
positive correlation with body mass index (BMI) a common risk factor for cardiovascular 
disease(Pepys & Hirschfield, 2003). Regarding its relationship to other relevant cytokines, CRP 
production in the liver is regulated by IL-6 (Black, 2004). An increase in CRP leads to an 
increase in other biomarkers as well, such as IL-6 and TNF-𝛼 levels.  
Interleukin-6 
A second cytokine that plays a significant role in the inflammatory process is interleukin-
6, or IL-6. IL-6 attracts white blood cells to the area that needs healing during inflammation and 
promotes accumulation of these cells (Barnes, 2011). White blood cells are agents of the immune 
system that respond to and fight off infection in order to protect the body. IL-6 also promotes B-
cell activity meaning that additional antibodies are produced in the body to help fight off foreign 
invaders (Barnes, 2011). B-cells are a specific branch of white blood cells that are created to 
produce antibodies. IL-6 not only affects B-cells, but it affects T-cells, another type of white 
blood cell. T-cells target and destroy abnormal cells in the body and typically require strict 
regulation in order to limit the number of cells they kill. However, IL-6 rescues T-cells from cell 
death, or apoptosis (Barnes, 2011). If T-cells are not being readily destroyed, then they can turn 
to healthy cells to attack. Therefore, it is suspected that IL-6 is involved in autoimmune diseases 
because they increase the number of T-cells in our bodies (Barnes, 2011). IL-6 is also considered 
one of the “chief stimulators” in the production of acute-phase proteins, which are the plasma 
proteins whose concentrations vary during acute inflammatory responses (Gabay, 2006). Acute 
inflammation is inflammation that is temporary, for example when a person falls and scrapes 
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their knee. Chronic inflammation, on the other hand, is inflammation that is long term and 
present throughout a person’s life. The main switch from acute inflammation to chronic 
inflammation is the recruitment of monocytes, a type of white blood cell, to the area of injury 
(Gabay, 2006). The recruitment of monocytes is one of the functions of IL-6 and therefore, IL-6 
is thought to be the key player in the transition from acute inflammation to chronic inflammation. 
During chronic inflammation, IL-6 then induces an innate immune response to affected cells and 
an adaptive immune response directed against reinfection (Gabay, 2006). Innate immune 
responses are the responses that every person has at birth (NCBI, 2016). It is our natural response 
to foreign invaders. Adaptive immune response is the response that is saved after the initial 
exposure, so that our body knows how best to fight off infection when re-exposed at a later point 
in life (NCBI, 2016). Overall, IL-6 has been shown to be positively associated with inflammation 
in the body, and its serum levels could be used to indicate related chronic diseases. As mentioned 
previously, the other type of inflammatory biomarker affected by CRP is TNF-⍺. 
Tumor Necrosis Factor-alpha 
Tumor Necrosis Factor-alpha (TNF-⍺) is another biomarker that plays a vital role in the 
process of inflammation. It was initially discovered for its antitumor activity but is now known to 
be an inflammatory mediator (Sethi & Aggarwal, 2008). It is a protein that is produced by white 
blood cells and eventually leads to the activation of other inflammatory genes (Popa, 2007). It is 
considered the most abundant early mediator at the site of injury and is the “master regulator” in 
pro-inflammatory cytokine production (Parameswaran & Patial, 2010). TNF-⍺ is produced by 
both monocytes and macrophages, and as it is produced, it activates other macrophages 
(Parameswaran & Patial, 2010). If there are high levels of TNF-⍺, then it is known that there has 
been an activation of inflammation. Other studies report that TNF-⍺ induces changes in both 
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lipid and glucose metabolism. It has inhibitory effects on insulin receptors, which can lead to 
diabetes, a risk factor for heart disease (Popa, 2007). It has also been shown to contribute to 
atherosclerosis for numerous reasons including recruitment and activation of white blood cells 
and other inflammatory molecules, promoting the expression of different adhesion molecules in 
vessel walls, and causing an inflammatory cascade inside arterial walls (Popa, 2007). TNF-⍺ 
clearly plays a major role in the activation and regulation of inflammation, and several factors 
point to the suspicion that it can indicate cardiovascular risk factors and disease. 
Each of these three inflammatory biomarkers are a result of chronic inflammation. If the 
biomarkers are elevated in the body, then this means that the body’s defense mechanism, white 
blood cells, are being called to an area to destroy infection or invaders. If there are no obvious 
foreigners, then it is thought that the white blood cells turn to healthy cell tissue and work to 
destroy it (Szalay, 2019). Sleep deprivation is thought to be one of the inducers of these 
biomarkers, therefore attracting of white blood cells over long periods of time (Trott et. al., 
2012). This ultimately affects the overall health of an individual and can increase the risk of 
chronic diseases.  
Sleep Duration, Quality, and Disorders and the Relationship to Inflammatory Biomarkers  
Sleep disruptions are examined in terms of sleep duration, quality, and disorders. Recent 
research suggests that both acute and ongoing sleep disruptions have a negative impact on one’s 
health in the short term and in terms of long term outcomes as indicated by increased risk for 
obesity, coronary artery disease, diabetes, and mortality (Patel, 2009). One commonly used 
method is polysomnography, which assess brain electrical activity, airflow, respiratory effort, 
and other physiological measures to determine sleep patterns. Commonly used indicators of 
sleep quality from polysomnography recordings include sleep onset latency (or the amount of 
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time it takes a person to fall asleep), the number of wake episodes a person experiences 
throughout the night, and how long those wake episodes are. These can impact the efficiency of a 
person’s sleep each night. Sleep efficiency is defined as the ratio of total sleep time to total time 
in bed (Reed & Sacco, 2016). Total sleep time is the time spent sleeping as opposed to the time 
spent watching TV, looking on one’s phone, reading, etc. (Reed & Sacco, 2016). Another way 
that sleep duration is commonly assessed is by using self-reported habitual sleep time (Reed & 
Sacco, 2016). This method is less reliable than a polysomnography due to the influence of social 
desirability bias and fallibility of human memory. Additionally, people may overestimate or 
underestimate their self-reported sleep patterns (Lauderdale, 2008). While many people may 
experience a low sleep efficiency or poor duration of sleep on its own, sleep disorders can also 
cause issues in these two areas. 
Duration and quality of sleep are disrupted by sleep disorders which is defined as any 
condition that changes the way you sleep and has an overall negative impact on your health 
(Mayo Clinic, 2019). Insomnia is one of the most common sleeping disorders (Basta, 2007). 
Statistics show that 25-33% of the population complains of difficulty falling asleep or difficulty 
staying asleep and around 10% complain of this being a chronic issue. Insomnia is often not 
discussed in society today and it is found that somewhere around 60% of all insomniacs do not 
seek medical assistance (Basta, 2007). Because of the lack of treatment, insomnia has large 
implications on public health.  
Another sleeping disorder that may be associated with cardiovascular disease and 
mortality risk and is obstructive sleep apnea (Motamedi et.al., 2009). Sleep apnea is when a 
person’s sleep is disturbed multiple times during the night due to an obstruction in respiration 
often due to the collapse of the nasal passageway. It is estimated that 20% of all adults have a 
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mild form of sleep apnea and 7% of the population have moderate or severe symptoms 
(Motamedi et.al., 2009). When sleep apnea occurs, it interrupts the sleep cycle leading to 
fragmented sleep wherein the patient may experience apnea (complete cessation of breathing) or 
hypopnea (partial cessation of breathing) for more than 30 times an hour in cases of severe apnea 
(Ruehland, 2009).  
Restless Leg Syndrome is another sleep disorder that may be related to chronic disease. 
Patients with restless leg syndrome experience an urge to move their legs while at rest, 
particularly at night (Trott et. al., 2012). This disrupts sleep patterns and is suspected to be 
associated with elevated inflammatory markers. The final sleep disorder that will be discussed is 
nightmare disorder which is defined as the repeated occurrence of nightmares that cause distress 
and cannot be attributed to another mental health disorder or substance use (American 
Psychiatric Association, 2017). Nightmares occur during REM sleep and are generally associated 
with symptoms of physical arousal. Nightmares often lead to awakenings, but this is not required 
to be diagnosed with a nightmare disorder. A nightmare sleep disorder is recognized as having 
one or more episodes per week lasting one to six months (Gieselmann et.al., 2019). It is 
suggested that these sleep disorders indicate a higher risk for future chronic conditions due to the 
disruption of sleep and the effect it has on inflammatory biomarkers such as C-reactive protein, 
Interleukin-6, and Tumor Necrosis Factor-⍺.  
Several studies involving sleep duration, sleep quality, and sleep disorders, many of 
which resulted in elevated CRP, IL-6, and TNF- 𝛼 and are summarized in Table 1. In studies 
looking at sleep duration, whether it be above or below the recommended amount of sleep, it was 
often found that there was elevated CRP (See Table 1). One study noted a U-shaped curve in 
results with CRP spiking at greater than 9 hours of sleep and less than 5 hours of sleep 
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(Grandner, 2013). However, one interesting finding in this study was that women tended to have 
elevated CRP with greater than 9 hours of sleep and men tended to have elevated CRP with less 
than 5 hours of sleep. Averaging these results among the overall population resulted in the U-
shaped curve but splitting by gender resulted in only one end of the spectrum showing elevation 
in CRP levels. Patel’s study (2009) found similar results with elevated CRP secondary to sleep 
that was greater than 9 hours. They also found elevations in IL-6 with long durations of sleep 
while TNF-𝛼 in participants who had shortened sleep duration (Patel, 2009). Shearer and 
colleagues (2001) studied participants’ levels of IL-6 and TNF-𝛼 and found increased levels with 
sleep loss. Similar to this, another study showed elevated CRP levels with sleep loss (Meier-
Ewert, 2004). Overall, most studies generally agree with the findings that any amount of sleep 
outside the usual 6-9 hours can lead to increased cytokine levels in the blood (see Table 1). 
However, there have been a couple of studies that have found contradicting results as well. 
Frey’s results showed that there were decreased levels of CRP and IL-6 when participants 
suffered from sleep deprivation, however they did note several other inflammatory biomarkers 
were elevated instead (2007).  
Sleep quality may also be a factor that is associated with increased inflammatory 
biomarker levels as shown in Table 1One study examined social connections and sleep 
efficiency and how that impacted levels of IL-6 (Friedman, 2005). Social connections and sleep 
efficiency were measured using a self-report survey and the participants were also given a health 
assessment by a professional (Friedman, 2005). This study found that women with good social 
connections and good sleep efficiency had relatively low levels of IL-6 whereas women with 
poor social connections and poor sleep efficiency had noticeably higher levels of IL-6 
(Friedman, 2005). Women with some combination of the two options had similarly low levels of 
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IL-6 as those who had both good social connections and good sleep efficiency (Friedman, 2005). 
Additionally, studies observed sleep quality using an electroencephalogram to measure brain 
waves and determine which stages of sleep the participant was experiencing (Hong, 2005). Poor 
sleep included several episodes of disrupted sleep and complaints of fatigue the following 
morning. They found that patients with lower sleep efficiency had higher levels of IL-6 the 
following morning than those patients with higher sleep efficiency (Hong, 2005). Both studies 
found elevated levels with decreased sleep efficiency. Although one would expect that 
Friedman’s study would find elevated levels with those participants with poor sleep efficiency 
and good social connections rather than only those who were rated as poor in both categories. 
This could be unreliable information, meaning that the results are not scientifically correct, as it 
is very difficult to measure one’s own sleep quality. Hong’s study (2005) was able to measure 
sleep efficiency using an EEG as well as self-report. 
Most research on the associations between sleep and inflammatory biomarkers focuses on 
several sleeping disorders including sleep apnea, insomnia, restless leg syndrome, and more. 
Razhegi (2011) conducted a broader study that focused on insomnia, restless leg syndrome, 
nightmares, narcolepsy, sleep apnea, and sleepwalking in dialysis patients. They used dialysis 
patients because they had noticed a pattern of sleep disorders among that group. When 
comparing CRP levels to those of a control group, the researchers found a notable elevation 
(Razhegi, 2011). One study with a particular focus on sleep apnea found that CRP levels were 
elevated in children who struggle with sleep apnea, and it was particularly high in those that 
complained of sleepiness and fatigue the following morning (Tauman, 2004). Another similar 
study found elevated levels of IL-6 and TNF-𝛼 in adult males with obstructive sleep apnea as 
compared to the control and they concluded that this could provide evidence that there is a 
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correlation to cardiovascular comorbidities (Ciftci, 2004). Other disorders besides sleep apnea 
have also been studied such as insomnia. Burgos and colleagues in 2005 used polysomnography 
to study patients with primary insomnia several days in a row. They measured serum levels of 
IL-6 during the evening and late at night and compared these serum levels to patients without 
any sleeping disorders. Their results showed a noticeable elevation of IL-6 levels in patients with 
primary insomnia (Burgos, 2005). On the other hand, patients with restless leg syndrome were 
found to have no correlating IL-6 or TNF-𝛼 levels, but elevated CRP levels were observed 
(Trotti et. al., 2012). Elevated cytokine levels were found in many research studies, not just those 
that were mentioned. Most provide support towards the theory that sleep does affect 
inflammation and poor sleep patterns could lead to a rise in inflammatory biomarkers (see Table 
1). Several studies have shown that factors such as sleep duration, sleep quality, and various 
sleep disorders can all lead to this elevation. The question at hand is whether this elevation in 
biomarker levels can further lead to things such as chronic diseases. 
Chronic Health Outcomes 
 Disease can be classified into two main categories, acute versus chronic. The current 
review focuses primarily on chronic disease and how it relates to increased inflammatory 
markers. Chronic disease is any disease or illness that is long developing and ongoing whereas 
acute disease is a sudden onset episode. Frequently, in case of chronic disease, patients will 
experience an acute exacerbation of symptoms that can be life-threatening. Patients with chronic 
diseases tend to have elevated inflammatory markers over extended periods because the body is 
undergoing stress from their disease, and their immune system is on constant overdrive (Pahwa, 
2019). This elevation of inflammatory biomarkers can have severe consequences on a person’s 
overall health and may lead to health problems such as cardiovascular disease and strokes. 
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Cardiovascular Disease (CVD) 
 The leading cause of death in the United States today is cardiovascular disease. 
Cardiovascular disease includes any issues with the heart such as heart attacks, coronary artery 
disease, congestive heart failure, arrhythmias, and heart valve problems (American Heart 
Association, 2014). Cardiovascular disease leads to damage to the heart which in turn triggers an 
immune response causing white blood cells to attack cardiac muscle (Ludwig-Maximilians-
Universität München, 2017). One factor linked to cardiovascular disease is an increased level of 
cytokines such as IL-6, TNF-𝛼, and CRP. These inflammatory biomarkers have 
proinflammatory, procoagulant (promotion of blood clotting), and growth promoting effects. 
They are produced directly in the arterial wall when elevated due to factors such as smoking and 
alcohol consumption (Mendall, 1997). TNF-𝛼 has been found to be associated with body mass 
index (BMI) which is also a common cardiac risk factor (Mendall, 1997).  Another study 
suggested that CRP may be a more significant biological risk factor of heart disease than 
cholesterol as previously believed (Notarangelo, 2017). In order to develop heart disease, 
cholesterol first must be modified before it leads to plaque formation on the arterial walls. The 
plaque is recognized as a “foreign body” and the immune system is then triggered, sending out 
inflammatory biomarkers such as CRP to respond to the attack (Notarangelo, 2017). Elevation of 
these inflammatory biomarkers can destroy the cell wall as it attacks the plaque and cholesterol, 
and this causes damage to the blood vessels creating an increased risk for heart attacks 
(Notarangelo, 2017). This implies a positive correlation between elevated inflammatory 
biomarkers and cardiovascular disease.  
 When looking deeper into studies, the correlation becomes more apparent, particularly 
with CRP. Table 2 summarizes trends of several studies that found relationships between 
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elevated CRP levels in patients either before or after experiencing a stroke or a cardiovascular 
issue such as coronary artery disease, acute coronary syndrome, myocardial infarction, or angina.  
Biasucci (2004) noted in their study of patients at the time of admission to the coronary unit in 
the hospital that there was a relationship between elevated IL-6 and elevated CRP, thus 
confirming the relevance of cytokine influence on the prognosis of unstable angina. They also 
reported that medications used to treat acute coronary syndrome were found to be most effective 
for lowering cardiac risk in patients who initially had high CRP levels (Biasucci, 2004). Another 
study analyzed a larger pool of patients who have already had experiences with CVD and noted 
that CRP blood levels showed consistent associations in those patients, although it was unclear 
as to the exact relationship between CVD and CRP elevation (Kaptoge, 2010).  
 Similar studies also found elevations in IL-6 and TNF-𝛼 to patients who have 
experienced a cardiovascular event (See Table 2). IL-6 was associated with increased 
atherosclerosis, which occurs when fatty plaque is deposited inside the artery walls (Kato, 2002). 
This is consistent with the discussion of the effect that IL-6 has on the development of CVD 
since atherosclerosis causes vessel diameter to decrease and eventually leads to CVD (Mayo 
Clinic, 2018). Because IL-6 increases as plaque buildup increases in the vessel walls, IL-6 could 
be an indicator of oncoming cardiac disease. As for TNF-𝛼, studies have shown that the presence 
it has in cardiac tissue suggests that it plays a role in the pathogenesis of cardiomyopathy, thus 
possibly being another indicator of CVD (Habib, 1996). Because these studies generally follow 
up on patients after a CVD event has occurred, it is difficult to conclude that these mentioned 
biomarkers affect the body which eventually leads to CVD or whether they are just signs that the 
body has had damage from the disease. In other words, do the elevated biomarkers cause the 
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disease or does CVD cause the elevated biomarkers due to the amount of stress and repair it is 
undergoing? 
While these particular reports studied patients only after they have experienced CVD, 
longitudinal studies have also been done in order to examine change over time. One group of 
researchers performed a longitudinal study over the course of 17 years on high risk, but healthy 
patients with follow-ups to look for death or myocardial infarctions (Kuller, 1996). They found a 
significant correlation between those patients with both elevated CRP and later developing CVD 
(Kuller, 1996). This study stood out since they focused on outcomes over an extended period and 
for following CRP levels prior to a heart attack or cardiovascular problem leading to death. Other 
factors were also accounted for in order to rule out the risk factors as being the only cause. For 
example, they found that CRP was notably elevated in smokers, even after accounting for the 
different factors that could affect their risk, such as the number of cigarettes per day or how long 
they have been a smoker (Kuller, 1996). This was again shown in another pre-CVD study as well 
as involving IL-6. This study was broad and observed the interleukin levels in over 14,000 men 
who were considered healthy. The patients who eventually had myocardial infarctions were 
observed to have increased IL-6 (Ridker, 2000). In addition to CVD, another health problem that 
is affected by chronic inflammation is a cerebrovascular accident. 
Strokes 
 A cerebrovascular accident, commonly known as a stroke, occurs when there is a lack of 
blood flow to the brain which causes active ischemia to cranial tissue. This is typically caused by 
a blocked vessel that supplies blood to the brain or by bleeding in the brain. Sleep is commonly 
believed to be a predictor of stroke risk. Studies have shown that short amounts of sleep 
increased risk by 18% while extended amounts of sleep increased the risk of stroke by 46% after 
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accounting for cardiovascular risk factors and comorbidities (Leng 2018). This risk is nearly 
twice the risk of a patient receiving the proper amount of sleep each night. In addition to these 
findings, there is also an association between patients who experience chronic inflammatory 
diseases such as systemic lupus erythematosus and rheumatoid arthritis, and those who 
experience strokes (Kamel & Iadecola, 2017). Patients who have these inflammatory illnesses 
have a significantly increased risk of having a stroke as compared to those with the common risk 
factors (Kamel & Iadecola, 2017). This raises the question of whether elevated inflammatory 
biomarkers such as CRP, IL-6, and TNF-𝛼 have implications for increased risk for having a 
stroke. 
 After analyzing several studies, a similar pattern was found between cytokine levels and 
strokes as was found with CVD (see Table 2). For example, Tancin Lambert and colleagues 
(2020) studied stroke patients with atrial fibrillation. This condition is a major risk factor for 
having a stroke, and they found that there were numerous cytokines that were associated with 
atrial fibrillation. They determined that there was a strong possibility that IL-6 could be very 
useful in identifying atrial fibrillation in patients which relates to strokes since almost a quarter 
of all strokes are related to atrial fibrillation (American Heart Association, 2017). Reports that 
studied TNF-α also examined risk factors of strokes and the TNF-α showing a positive 
association with typical risk factors such as cholesterol, blood pressure, age, smoking, and BMI 
(Cui, 2012). In demonstrating the relationship between these biomarkers and common risk 
factors, it becomes more evident that there could be an association between elevated biomarkers 
and the prognosis of strokes. However, risk factors were not the only aspect examined; patients 
with strokes were studied as well. Whiteley completed a three-year study from 2002-2005 
involving follow-ups with patients post-stroke in order to test for CRP and IL-6 levels in the 
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blood as well as the outcomes of the cases. It was found that elevated levels were associated with 
poor outcomes later in life, although they could not determine a model to predict recurrent 
strokes or outcomes (Whiteley, 2005). Several other studies showed results consistent with these 
outcomes, as seen in Table 1. 
 Overall, it is clear that there is an association between inflammatory biomarkers and 
chronic health outcomes, but a definite relationship cannot be established for several reasons. 
Multiple studies addressed their limitations, but in many cases the limitations impede the 
findings. Many studies had very small sample sizes due to the availability of patients or difficulty 
recruiting patients. Without larger sample sizes, results may be affected due to increased margin 
of error and decreased representation of the population. Even in those studies that had large 
sample sizes, problems with causation versus correlation were apparent. Many studies only 
included patients after they have experienced an acute health crisis. By that point most of them 
already had elevated biomarker levels, and it cannot be determined whether the biomarkers were 
elevated prior to the event or after the event. This is due to not being able to accurately predict 
the who, what, or when of a health crisis. When you are unsure if someone will eventually have a 
stroke, it is difficult to collect data. Some research addressed both issues and included large 
sample sizes as well as using longitudinal studies of high-risk patients who may or may not 
develop CVD or stroke. However, even with these studies it can be challenging to show that the 
inflammatory biomarkers are elevated because the patient is about to have an acute crisis or if 
they are elevated for some other reason in the body such as hypertension or high cholesterol 
which are risk factors of many chronic health problems. There is a positive correlation between 
inflammation and chronic disease, although determining whether there is a causal effect would 
require more research to be done. Also, due to ethical concerns with conducting experiments for 
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high risk factors, the effect of inflammation on chronic disease cannot be easily examined since 
researchers cannot experimentally manipulate these variables. This correlation can be related 
back to the discussion of sleep and its impact on inflammation. Poor sleep can lead to an 
elevation of inflammatory biomarkers in the body and having these biomarkers being elevated 
chronically may lead to the development of chronic health disease. 
Conclusion 
 Based on prior research on the relationship between sleep and inflammatory biomarker 
levels as well as between chronic health disease and inflammatory biomarker levels, several 
conclusions may be drawn. When first examining the effects of sleep on inflammation, it can be 
concluded that several factors leading to an unusual amount of sleep, or to disturbed sleep, 
causing the body to respond by signaling the release of inflammatory markers. Studies have 
consistently found elevations in CRP, IL-6, and TNF-𝛼 when sleep duration was altered, sleep 
quality was decreased, or in patients with several different sleep disorders. If a person is 
consistently experiencing these different effects, then the body will also continuously be 
experiencing an inflammatory response. As mentioned earlier, the release of these biomarkers 
can be beneficial when there is a need for repair and healing in the body. However, when there is 
no need for inflammation, these biomarkers have no specific location to go to, and they will 
spread out and begin attacking healthy tissue, which will have negative consequences on the 
body. 
 When looking at the effects of inflammation on chronic disease, it becomes more 
challenging to make a definitive conclusion. While many studies point towards an association 
between the two, most are unable to establish a clear causal connection due to ethical reasons 
since inflammation cannot be experimental manipulated in experimental settings. In many 
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studies, it is undetermined whether the inflammation levels came first and caused the chronic 
disease or worsened chronic disease or whether the chronic health disease is causing 
inflammation to increase inside the body. In order to determine this, more experimental 
longitudinal studies need to be conducted. If researchers can begin by looking at inflammatory 
biomarker levels in patients throughout their lifetime, they will be able to see how these levels 
are affected before and after they develop chronic disease and compare these results to patients 
experiencing similar problems. The challenge with this is that not only does it take time to 
conduct longitudinal studies, but it is also difficult to control factors that may cause different 
reactions in patients, such as stress levels, careers, living locations, etc. Without being able to 
control these factors, it may never be known definitively whether the elevated cytokine levels are 
increasing the risk of chronic diseases or if other factors that lead to chronic disease.  
 Although it can be established that sleep does impact levels of inflammatory biomarkers 
in the body, it is difficult to say whether those elevated biomarkers do lead to chronic diseases. 
There is still a lack of clarity that this very well could be the case due to the handful of 
longitudinal studies done regarding chronic disease and biomarker levels. These studies, as 
mentioned earlier, have found that there is a positive association between the two variables, and 
this could potentially indicate that chronically elevated biomarkers may increase the risk of 
developing chronic disease later in life. Because the biomarkers are elevated, this means that the 
body’s immune system is active. However, when there is no apparent reason for it to be active, 
the body is attacking cells that do not need to be destroyed. As a result, this attack can lead to the 
destruction of vessels and tissue that is vital to keep intact in order to stay in good health. Sleep 
changes may predict an increase in inflammatory biomarker levels, but the question at hand is 
whether this, in turn, increases the risk of developing chronic diseases. While this does seem to 
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be the cause, more research needs to be conducted about the causal effect between inflammatory 
biomarkers and chronic health problems to confidently come to this conclusion. Until there is 
extensive research in this area, it cannot be confirmed that the lack of quality sleep can lead to 
chronic diseases. Although a definitive relationship cannot yet be fully established, these results 
show significant promise regarding the future of sleep studies and health. By understanding how 
inflammation impacts chronic health disease, other issues that affect inflammation can also be 
studied and identified as causes of chronic health disease. This research also highlights the 
importance of studying sleep and how adjusting one’s sleep is a simple way to live a healthier 
life and decrease the risk of poor health in the future. These findings could be used to emphasize 
sleep disorder interventions as a method to reduce inflammation in patients who suffer from 
chronic disease. Overall, these studies could change the way health professionals talk about sleep 
and other causes of inflammation and emphasize the long-term impact that it can have on a 
person’s body and health. 
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Appendix 
Table 1 
Studies Focused on Sleep and Inflammatory Biomarkers 
Study Year 
Sample 
Size Sleep Disorder CRP IL-6 TNF-⍺ 
Burgos 2005 22 Insomnia N/A Elevated N/A 
Firat Guven 2012 76 Sleep Apnea Elevated N/A N/A 
Frey 2007 19 Sleep Deprivation Decrease Decrease N/A 
Friedman 2005 74 Sleep Efficiency N/A Elevated N/A 
Grandner 2013 5587 Sleep Duration Elevated N/A N/A 
Guilleminault 2004 239 Sleep Apnea Elevated N/A N/A 
Hong 2005 70 Sleep Quality N/A Elevated N/A 
Kaditis 2005 141 Sleep Apnea No relationship N/A N/A 
Kokturk 2005 173 Sleep Apnea Elevated N/A N/A 
Larkin 2005 143 Sleep Apnea Elevated N/A N/A 
Meier-Ewert 2004 20 Sleep Loss Elevated N/A N/A 
Patel 2009 614 Sleep Duration Elevated with long duration Elevated with long duration Elevated with short duration 
Razeghi 2012 108 Sleep Disorders Elevated N/A N/A 
Schiza 2010 528 Sleep Apnea Reduced with CPAP N/A N/A 
Shearer 2001 42 Sleep Loss N/A Elevated Elevated  
Song 1998 30 Sleep Disorders N/A Elevated N/A 
Tauman 2004 81 Sleep Apnea Elevated N/A N/A 
Trotti 2012 137 Restless Leg Syndrome Elevated No correlation No correlation 
Ciftci 2004 43 Sleep Apnea N/A Elevated Elevated 
Vgontzas 2004 25 Sleep Restriction N/A Elevated Elevated in men 
Vgontzas 1997 41 Sleep Disorders N/A Elevated Elevated 
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Table 2: 
Studies Focused on Chronic Health and Disease and Inflammatory Biomarkers 
Study Year Sample Size CVD or Stroke CRP IL-6 TNF-⍺ 
Biasucci et al. 2004 67 patients CVD Elevated Elevated N/A 
Bokhari et al. 2014 131 patients Stroke N/A N/A Elevated 
Ma et al. 2020 588 patients Stroke Elevated Elevated Elevated 
Benamer et al. 1998 195 patients CVD No correlation N/A N/A 
Eshaghi et al. 2019 618 Patients CVD Elevated N/A N/A 
Jenny et al. 2002 5201 patients CVD n/a  Elevated- 5% N/A 
Kuller et al. 1996 737 patients CVD Elevated N/A N/A 
Kaptoge et al. 2010 160,309 patients CVD and Stroke Elevated N/A N/A 
Liuzzo et al. 1994 92 patients CVD Elevated N/A N/A 
Mendall et al. 1997 198 Patients CVD N/A Elevated Elevated 
Napoli et al. 2001 193 Patients Stroke Elevated N/A N/A 
Ridker et al. 2000 14,916 patients CVD Elevated Elevated N/A 
Lindmark et al. 2001 3489 patients CVD N/A Elevated N/A 
Kato et al. 2002 156 patients CVD N/A Elevated N/A 
Tancin Lambert et al. 2020 26 patients stroke N/A Elevated N/A 
Volpato et al. 2001 620 patients CVD N/A Elevated N/A 
Whiteley et al. 2009 844 patients stroke Elevated Elevated N/A 
Woodward et al. 1999 1574 patients CVD N/A Correlation N/A 
Zimmermann et al. 1998 280 patients CVD Elevated N/A N/A 
Zempelas et al. 2005 1514 patients CVD 33% lower CRP 33% lower  21% lower 
Smith and Allen 1992 Mice, unknown CVD N/A N/A Elevated 
Habib et al. 1996 40 patients CVD N/A N/A Elevated 
Latini et al. 1994 18 patients CVD N/A N/A Elevated 
Cui et al. 2012 2415 patients Stroke N/A N/A Elevated 
 
